000148186 001__ 148186
000148186 005__ 20250114175434.0
000148186 0247_ $$2doi$$a10.1210/clinem/dgac412
000148186 0248_ $$2sideral$$a130347
000148186 037__ $$aART-2022-130347
000148186 041__ $$aeng
000148186 100__ $$aRamos-Caceres, Maria
000148186 245__ $$aTriglyceride Metabolism Modifies Lipoprotein(a) Plasma Concentration
000148186 260__ $$c2022
000148186 5060_ $$aAccess copy available to the general public$$fUnrestricted
000148186 5203_ $$aBackground Lipoprotein(a) (Lp(a)) is a significant cardiovascular risk factor. Knowing the mechanisms that regulate its concentration can facilitate the development of Lp(a)-lowering drugs. This study analyzes the relationship between triglycerides (TGs) and Lp(a) concentrations, cross-sectionally and longitudinally, and the influence of the number and composition of TG-rich lipoproteins, and the APOE genotype. Methods Data from Aragon Workers Health Study (AWHS) (n = 5467), National Health and Nutrition Examination Survey III phase 2 (n = 3860), and Hospital Universitario Miguel Servet (HUMS) (n = 2079) were used for cross-sectional TG and Lp(a) relationship. Lp(a) intrasubject variation was studied in AWHS participants and HUMS patients with repeated measurements. TG-rich lipoproteins were quantified by nuclear magnetic resonance in a subsample from AWHS. Apolipoproteins B and E were quantified by Luminex in very low-density lipoprotein (VLDL) isolated by ultracentrifugation, from HUMS samples. APOE genotyping was carried in AWHS and HUMS participants. Regression models adjusted for age and sex were used to study the association. Results The 3 studies showed an inverse relationship between TG and Lp(a). Increased VLDL number, size, and TG content were associated with significantly lower Lp(a). There was an inverse association between the apoE concentration in VLDL and Lp(a). No significant association was observed for apolipoprotein (apo)B. Subjects carrying the apoE2/E2 genotype had significantly lower levels of Lp(a). Conclusion Our results show an inverse relationship Lp(a)-TG. Subjects with larger VLDL size have lower Lp(a), and lower values of Lp(a) were present in patients with apoE-rich VLDL and apoE2/E2 subjects. Our results suggest that bigger VLDLs and VLDLs enriched in apoE are inversely involved in Lp(a) plasma concentration.
000148186 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B14-7R$$9info:eu-repo/grantAgreement/ES/ISCIII/FIS/PI19-00694$$9info:eu-repo/grantAgreement/ES/MINECO/PI18-01777
000148186 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000148186 590__ $$a5.8$$b2022
000148186 591__ $$aENDOCRINOLOGY & METABOLISM$$b31 / 144 = 0.215$$c2022$$dQ1$$eT1
000148186 592__ $$a1.776$$b2022
000148186 593__ $$aBiochemistry$$c2022$$dQ1
000148186 593__ $$aBiochemistry (medical)$$c2022$$dQ1
000148186 593__ $$aMedicine (miscellaneous)$$c2022$$dQ1
000148186 593__ $$aEndocrinology$$c2022$$dQ1
000148186 593__ $$aEndocrinology, Diabetes and Metabolism$$c2022$$dQ1
000148186 593__ $$aClinical Biochemistry$$c2022$$dQ1
000148186 594__ $$a9.9$$b2022
000148186 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000148186 700__ $$0(orcid)0000-0002-9647-0108$$aLamiquiz-Moneo, Itziar$$uUniversidad de Zaragoza
000148186 700__ $$aCenarro, Ana
000148186 700__ $$aCalmarza, Pilar
000148186 700__ $$aMarco-Benedi, Victoria
000148186 700__ $$aBea, Ana M.
000148186 700__ $$0(orcid)0000-0001-6650-8294$$aMateo-Gallego, Rocio$$uUniversidad de Zaragoza
000148186 700__ $$0(orcid)0000-0002-1309-4363$$aPuzo, Jose$$uUniversidad de Zaragoza
000148186 700__ $$aOrdovas, Jose M.
000148186 700__ $$0(orcid)0000-0001-7043-0952$$aCiveira, Fernando$$uUniversidad de Zaragoza
000148186 700__ $$0(orcid)0000-0003-3963-0846$$aLaclaustra, Martin$$uUniversidad de Zaragoza
000148186 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000148186 7102_ $$11003$$2027$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Anatom.Embriol.Humana
000148186 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000148186 773__ $$g107, 9 (2022), E3594-E3602$$pJ. clin. endocrinol. metab.$$tJOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM$$x0021-972X
000148186 8564_ $$s355187$$uhttps://zaguan.unizar.es/record/148186/files/texto_completo.pdf$$yVersión publicada
000148186 8564_ $$s507687$$uhttps://zaguan.unizar.es/record/148186/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000148186 909CO $$ooai:zaguan.unizar.es:148186$$particulos$$pdriver
000148186 951__ $$a2025-01-14-15:49:05
000148186 980__ $$aARTICLE